Clinical Trials Directory

Trials / Completed

CompletedNCT01918592

PET/MRI and Biomarkers in Bladder Cancer

PET/MRI and Biomarkers in Clinical Staging of Bladder Cancer and in the Estimation of Neoadjuvant Chemotherapy Response Prior to Radical Cystectomy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Turku University Hospital · Other Government
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Muscle invasive bladder cancer is an aggressive malignancy. Currently the investigators lack accurate imaging technologies in clinical staging and estimation of response to neoadjuvant chemotherapy as well as prognostic biomarkers. In the current study novel imaging modality (MRI/PET) is utilized to stage bladder cancer prior to transurethral resection of bladder-tumor and after neoadjuvant chemotherapy. Also prognostic biomarkers are studied from TUR-BT tissues, blood and urine to estimate response to neoadjuvant chemotherapy.

Conditions

Interventions

TypeNameDescription
DEVICEMRI/acetate-PET imaging

Timeline

Start date
2013-08-01
Primary completion
2016-03-01
Completion
2016-11-01
First posted
2013-08-08
Last updated
2018-04-18

Locations

3 sites across 1 country: Finland

Source: ClinicalTrials.gov record NCT01918592. Inclusion in this directory is not an endorsement.

PET/MRI and Biomarkers in Bladder Cancer (NCT01918592) · Clinical Trials Directory